Why you need pharmacogenetic tests when taking Vancomycin

Vancomycin

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Indication

For the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci.

CPIC Dosing Guideline for rasburicase and G6PD

Summary

Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The G6PD gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence.

Annotation

Aug 2014

Accepted article preview online May 2014, advance online publication 11 June 2014

  • Guidelines regarding the use of pharmacogenomic tests in determining whether rasburicase treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC).
  • Excerpt from the 2014 rasburicase guideline:
    • “As stated above, rasburicase is contraindicated by the FDA, the EMA, and PMDA in those with G6PD deficiency (32-34) (see Table 2). If, on the basis of genotyping, a deficient status can be unambiguously assigned to a patient, that would be a sufficient contraindication to the use of rasburicase. However, due to the limitations of genetic testing (discussed above), in most cases it is necessary to perform G6PD enzyme testing to assign G6PD status.”
  • These guidelines are applicable to
    • neonates
    • pediatrics
    • adults
  • ———–

Pharmacogenetic tests

  • We are working with doctors and medical sales reps, medxprime.com to prevent adverse drug reactions and promote patient safety. Contact Connie Dello Buono 408-854-1883 motherhealth@gmail.com if you want to add this service /test as added tool in your practice and  for medical sales reps (as we are hiring in all states in the USA).

One million challenge to help others with adverse drug reactions and ensure safe medications

Challenge

What: A challenge to help reduce drug adverse reactions with education and support group , educating about pharmacogenetic tests , one family at a time and ensuring safe medications in many positive ways with support group, family support, provider support and other education ways.

Join

To join: Sign the medication safety pledge and a schedule training/webinar follows with weekly accountability, tasks that lead to education, support group to promote safety in medications, prevention of adverse drug reactions, promoting health

Task

Daily/weekly task: To share or educate others in person or social network
Education related: tasks not only include pharmacogenetics tests promotion and education but helping a seniors in medication management thru alerts or support groups or information gathering/sharing
Any suggestions are welcome.
We need a million signatures/members. Contact Connie Dello Buono at motherhealth@gmail.com 408-854-1883 to join the challenge or pledge.  The public is welcome and so are the professionals.